Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.65 |
| ▸ | ANPEP | P15144 | 2/20 | 0.65 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764379 | 1.00 | MME (0.65) | MMEANPEPECE1 | |
| SCHEMBL26126059 | 0.99 | MME (0.64) | MMEANPEPECE1 | |
| SCHEMBL1763939 | 0.92 | MME (0.55) | MMEANPEPECE1 | |
| SCHEMBL30602593 | 0.92 | MME (0.55) | MMEANPEPECE1 | |
| SCHEMBL12596609 | 0.92 | MME (0.55) | MMEANPEPECE1 | |
| SCHEMBL1764631 | 0.92 | ANPEP (0.52) | MMEANPEP | |
| SCHEMBL1764171 | 0.91 | MME (0.55) | MMEANPEPECE1 | |
| SCHEMBL12596605 | 0.91 | MME (0.55) | MMEANPEPECE1 | |
| SCHEMBL20526402 | 0.91 | MME (0.55) | MMEANPEPECE1 | |
| SCHEMBL1764066 | 0.90 | MME (0.52) | MMEANPEPECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391710-B2 | Method for the industrial preparation of the disodium salt of ((2S)-3-([1,1′-biphenyl]-4-yl-2-((hydroxy((1R)-1-(((1-(isobutyryloxy)ethoxy)carbonyl)amino)ethyl)phosphoryl) methyl)propanoyl)-l-alanine | KOS THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | claimed |
| CN-114787171-B | Industrial preparation method of compound | 智腾大中华区有限公司 | 2024-05-14 | — | — | CN | claimed |
| EP-4073080-B1 | PROCESS FOR INDUSTRIAL PREPARATION OF THE DISODIUM SALT OF ((2S)-3-([1,1'-BIPHENYL]-4-YL)-2-((HYDROXY((1R)-1-(((1-(ISOBUTYRYLOXY)ETHOXY)CARBONYL)AMINO)ETHYL)PHOSPHORYL)METHYL)PROPANOYL)-L-ALANINE | KOS THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | claimed |
| US-20230041504-A1 | METHOD FOR THE INDUSTRIAL PREPARATION OF THE DISODIUM SALT OF ((2S)-3-([1,1'-BIPHENYL]-4-YL)-2-((HYDROXY((1R)-1-(((1-(ISOBUTYRYLOXY)ETHOXY)CARBONYL)AMINO)ETHYL)PHOSPHORYL) METHYL)PROPANOYL)-L-ALANINE | KOS THERAPEUTICS, INC. | 2023-02-09 | — | — | US | claimed |
| EP-4073080-A1 | PROCESS FOR INDUSTRIAL PREPARATION OF THE DISODIUM SALT OF ((2S)-3-([1,1'-BIPHENYL]-4-YL)-2-((HYDROXY((1R)-1-(((1-(ISOBUTYRYLOXY)ETHOXY)CARBONYL)AMINO)ETHYL)PHOSPHORYL)METHYL)PROPANOYL)-L-ALANINE | Pharmaleads (FR) | 2022-10-19 | — | — | EP | claimed |
| WO-2021116617-A1 | PROCESS FOR INDUSTRIAL PREPARATION OF THE DISODIUM SALT OF ((2S)-3-([1,1'-BIPHENYL]-4-YL)-2-((HYDROXY((1R)-1-(((1-(ISOBUTYRYLOXY)ETHOXY)CARBONYL)AMINO)ETHYL)PHOSPHORYL)METHYL)PROPANOYL)-L-ALANINE | PHARMALEADS (FR) | 2021-06-17 | — | — | WO | claimed |
| US-12391710-B2 | Method for the industrial preparation of the disodium salt of ((2S)-3-([1,1′-biphenyl]-4-yl-2-((hydroxy((1R)-1-(((1-(isobutyryloxy)ethoxy)carbonyl)amino)ethyl)phosphoryl) methyl)propanoyl)-l-alanine | KOS THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12391710-B2 | Method for the industrial preparation of the disodium salt of ((2S)-3-([1,1′-biphenyl]-4-yl-2-((hydroxy((1R)-1-(((1-(isobutyryloxy)ethoxy)carbonyl)amino)ethyl)phosphoryl) methyl)propanoyl)-l-alanine | KOS THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| CN-114787171-B | Industrial preparation method of compound | 智腾大中华区有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-114787171-B | Industrial preparation method of compound | 智腾大中华区有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4073080-B1 | PROCESS FOR INDUSTRIAL PREPARATION OF THE DISODIUM SALT OF ((2S)-3-([1,1'-BIPHENYL]-4-YL)-2-((HYDROXY((1R)-1-(((1-(ISOBUTYRYLOXY)ETHOXY)CARBONYL)AMINO)ETHYL)PHOSPHORYL)METHYL)PROPANOYL)-L-ALANINE | KOS THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-4073080-B1 | PROCESS FOR INDUSTRIAL PREPARATION OF THE DISODIUM SALT OF ((2S)-3-([1,1'-BIPHENYL]-4-YL)-2-((HYDROXY((1R)-1-(((1-(ISOBUTYRYLOXY)ETHOXY)CARBONYL)AMINO)ETHYL)PHOSPHORYL)METHYL)PROPANOYL)-L-ALANINE | KOS THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230041504-A1 | METHOD FOR THE INDUSTRIAL PREPARATION OF THE DISODIUM SALT OF ((2S)-3-([1,1'-BIPHENYL]-4-YL)-2-((HYDROXY((1R)-1-(((1-(ISOBUTYRYLOXY)ETHOXY)CARBONYL)AMINO)ETHYL)PHOSPHORYL) METHYL)PROPANOYL)-L-ALANINE | KOS THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2017093322-A1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE PAIN | PHARMALEADS (FR) | 2017-06-08 | — | — | WO | disclosed |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS (FR) | 2014-06-12 | — | — | US | disclosed |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS (FR) | 2014-06-12 | — | — | US | disclosed |
| US-8703747-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2014-04-22 | — | — | US | disclosed |
| US-8703747-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS | 2011-05-26 | — | — | US | disclosed |
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041504-A1 | METHOD FOR THE INDUSTRIAL PREPARATION OF THE DISODIUM SALT OF ((2S)-3-([1,1'-BIPHENYL]-4-YL)-2-((HYDROXY((1R)-1-(((1-(ISOBUTYRYLOXY)ETHOXY)CARBONYL)AMINO)ETHYL)PHOSPHORYL) METHYL)PROPANOYL)-L-ALANINE | CHAMP1, AADAT, PTMS | MME 1021/4885ANPEP 191/4885ECE1 546/4885 |
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | MME 3670/4885ANPEP 2038/4885ECE1 4157/4885 |
| US-12391710-B2 | Method for the industrial preparation of the disodium salt of ((2S)-3-([1,1′-biphenyl]-4-yl-2-((hydroxy((1R)-1-(((1-(isobutyryloxy)ethoxy)carbonyl)amino)ethyl)phosphoryl) methyl)propanoyl)-l-alanine | CHAMP1, PEAK1, AADAT | MME 994/4885ANPEP 171/4885ECE1 349/4885 |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | MME 3490/4885ANPEP 2062/4885ECE1 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.